NASDAQ:ALRN Aileron Therapeutics (ALRN) Stock Price, News & Analysis $2.55 +0.04 (+1.59%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$2.50▼$2.7450-Day Range$2.51▼$3.7752-Week Range$1.01▼$7.42Volume56,065 shsAverage Volume74,706 shsMarket Capitalization$55.11 millionP/E RatioN/ADividend YieldN/APrice Target$19.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Aileron Therapeutics alerts: Email Address Aileron Therapeutics MarketRank™ Stock AnalysisAnalyst RatingStrong Buy3.50 Rating ScoreUpside/Downside645.1% Upside$19.00 Price TargetShort InterestHealthy1.66% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.44Based on 2 Articles This WeekInsider TradingSelling Shares$248,685 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.36) to ($1.38) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.38 out of 5 starsMedical Sector557th out of 936 stocksPharmaceutical Preparations Industry252nd out of 436 stocks 3.8 Analyst's Opinion Consensus RatingAileron Therapeutics has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAileron Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Aileron Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.66% of the float of Aileron Therapeutics has been sold short.Short Interest Ratio / Days to CoverAileron Therapeutics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aileron Therapeutics has recently increased by 13.81%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAileron Therapeutics does not currently pay a dividend.Dividend GrowthAileron Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALRN. Previous Next 1.9 News and Social Media Coverage News SentimentAileron Therapeutics has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Aileron Therapeutics this week, compared to 1 article on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aileron Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $248,685.00 in company stock.Percentage Held by InsidersOnly 5.57% of the stock of Aileron Therapeutics is held by insiders.Percentage Held by Institutions90.89% of the stock of Aileron Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Aileron Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Aileron Therapeutics are expected to decrease in the coming year, from ($1.36) to ($1.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aileron Therapeutics is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aileron Therapeutics is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAileron Therapeutics has a P/B Ratio of 1.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Aileron Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIHow to build the ultimate dividend portfolioThere’s a free dividend workshop that shows how anyone can build the ultimate dividend workshop in 3 basic steps? PLUS: You’ll get the names and tickers of the Best Dividend Stocks for FREE… This way, by the time you finish the workshop you’ll be fully equipped with the knowledge to start unlocking dividend checks for yourself… Over and over again.Click here and I’ll show you how to build the ultimate dividend portfolio. About Aileron Therapeutics Stock (NASDAQ:ALRN)Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.Read More ALRN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALRN Stock News HeadlinesJuly 1, 2024 | prnewswire.comAileron Therapeutics to be Included in the Russell Microcap® IndexMay 16, 2024 | finanznachrichten.deAileron Therapeutics, Inc.: Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 15, 2024 | msn.comALRN Stock Earnings: Aileron Therapeutics Reported Results for Q1 2024May 15, 2024 | tmcnet.comAileron Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsMay 15, 2024 | globenewswire.comAileron Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsMay 6, 2024 | globenewswire.comAileron Therapeutics to Present at Two Upcoming Investor ConferencesMay 3, 2024 | seekingalpha.comALRN Aileron Therapeutics, Inc.July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 3, 2024 | finance.yahoo.comAileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 MillionMay 3, 2024 | globenewswire.comAileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 MillionMay 2, 2024 | finance.yahoo.comAileron reports data from Cohort 1 of Phase Ib inhaled IPF treatment trialMay 1, 2024 | globenewswire.comAileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 MillionMay 1, 2024 | globenewswire.comAileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)April 16, 2024 | investorplace.comALRN Stock Earnings: Aileron Therapeutics Reported Results for Q4 2023April 16, 2024 | finanznachrichten.deAileron Therapeutics, Inc.: Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateApril 15, 2024 | globenewswire.comAileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 12, 2024 | markets.businessinsider.comAileron Therapeutics CEO Manuel Aivado Steps Down; Names Brian Windsor ReplacementSee More Headlines Receive ALRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aileron Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/20/2024Today7/26/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ALRN CUSIPN/A CIK1420565 Webwww.aileronrx.com Phone(617) 995-0900FaxN/AEmployees15Year FoundedN/APrice Target and Rating Average Stock Price Target$19.00 High Stock Price Target$19.00 Low Stock Price Target$19.00 Potential Upside/Downside+645.1%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($3.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,730,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-95.55% Return on Assets-31.15% Debt Debt-to-Equity RatioN/A Current Ratio2.82 Quick Ratio2.82 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.41 per share Price / Book1.81Miscellaneous Outstanding Shares21,610,000Free Float20,411,000Market Cap$55.11 million OptionableNot Optionable Beta2.23 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. James Brian Windsor Ph.D. (Age 58)CEO, President & Director Comp: $715.92kKey CompetitorsUnity BiotechnologyNASDAQ:UBXCumberland PharmaceuticalsNASDAQ:CPIXVaccinexNASDAQ:VCNXESSA PharmaNASDAQ:EPIX2seventy bioNASDAQ:TSVTView All CompetitorsInsiders & InstitutionsOf Texas/Texas Am I UniversitySold 4,707 sharesTotal: $15,297.75 ($3.25/share)Of Texas/Texas Am I UniversitySold 1,900 sharesTotal: $6,270.00 ($3.30/share)Of Texas/Texas Am I UniversitySold 9,342 sharesTotal: $30,361.50 ($3.25/share)Of Texas/Texas Am I UniversitySold 9,577 sharesTotal: $31,604.10 ($3.30/share)Of Texas/Texas Am I UniversitySold 1,740 sharesTotal: $5,672.40 ($3.26/share)View All Insider TransactionsView All Institutional Transactions ALRN Stock Analysis - Frequently Asked Questions How have ALRN shares performed this year? Aileron Therapeutics' stock was trading at $3.05 on January 1st, 2024. Since then, ALRN stock has decreased by 16.4% and is now trading at $2.55. View the best growth stocks for 2024 here. How were Aileron Therapeutics' earnings last quarter? Aileron Therapeutics, Inc. (NASDAQ:ALRN) issued its quarterly earnings data on Monday, May, 20th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by $0.72. When did Aileron Therapeutics' stock split? Aileron Therapeutics shares reverse split on the morning of Thursday, November 10th 2022. The 1-20 reverse split was announced on Thursday, November 10th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 10th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Aileron Therapeutics IPO? Aileron Therapeutics (ALRN) raised $61 million in an initial public offering (IPO) on Thursday, June 29th 2017. The company issued 3,800,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers. How do I buy shares of Aileron Therapeutics? Shares of ALRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Aileron Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aileron Therapeutics investors own include Portola Pharmaceuticals (PTLA), Acasti Pharma (ACST), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Allena Pharmaceuticals (ALNA), OPKO Health (OPK) and Amarin (AMRN). This page (NASDAQ:ALRN) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aileron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aileron Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALRN Stock Alerts